Insulin-like growth factor-1 induces hyperproliferation of PKD1 cystic cells via a Ras/Raf dependent signalling pathway

Autosomal dominant polycystic kidney disease (ADPKD) largely results from mutations in the PKD1 gene leading to hyperproliferation of renal tubular epithelial cells and consequent cyst formation. Rodent models of PKD suggest that the multifunctional hormone insulin-like growth factor-1 (IGF-1) could play a pathogenic role in renal cyst formation. In order to test this possibility, conditionally immortalized renal epithelial cells were prepared from normal individuals and from ADPKD patients with known germline mutations in PKD1. All patient cell lines had a decreased or absence of polycystin-1 but not polycystin-2. These cells had an increased sensitivity to IGF-1 and to cyclic AMP, which required phosphatidylinositol-3 (PI3)-kinase and the mitogen-activated protein kinase, extracellular signal-regulated protein kinase (ERK) for enhanced growth. Inhibition of Ras or Raf abolished the stimulated cell proliferation. Our results suggest that haploinsufficiency of polycystin-1 lowers the activation threshold of the Ras/Raf signalling system leading to growth factor-induced hyperproliferation. Inhibition of Ras or Raf activity may be a therapeutic option for decreasing tubular cell proliferation in ADPKD

Design parameters for ionic liquid–molecular solvent blend electrolytes to enable stable Li metal cycling within Li–O2 batteries

Effective utilization of Li-metal electrodes is vital for maximizing the specific energy of lithium–oxygen (Li–O2) batteries. Many conventional electrolytes that support Li–O2 cathode processes (e.g., dimethyl sulfoxide, DMSO) are incompatible with Li-metal. Here, a wide range of ternary solutions based on solvent, salt, and ionic liquid (IL) are explored to understand how formulations may be tailored to enhance stability and performance of DMSO at Li-metal electrodes. The optimized formulations therein facilitate stable Li plating/stripping performances, Columbic efficiencies >94%, and improved performance in Li–O2 full cells. Characterization of Li surfaces reveals the suppression of dendritic deposition and corrosion and the modulation of decomposition reactions at the interface within optimized formulations. These observations are correlated with spectroscopic characterization and simulation of local solvation environments, indicating the persistent importance of DMSO–Li+-cation interactions. Therein, stabilization remains dependent on important molar ratios in solution and the 4:1 solvent-salt ratio, corresponding to ideal coordination spheres in these systems, is revealed as critical for these ternary formulations. Importantly, introducing this stable, non-volatile IL has negligible disrupting effects on the critical stabilizing interactions between Li+ and DMSO and, thus, may be carefully introduced to tailor other key electrolyte properties for Li–O2 cells

Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats

Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal monoamine oxidase (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake, than in tissue homogenates. In the present study, the effects of amezinium on the deamination of noradrenaline were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the catecholamine transporter is non-neuronal uptake. In addition, another drug that is both a substrate of uptake and a MAO inhibitor, debrisoquine, was investigated in the study. The first aim of the study was to show whether amezinium and debrisoquine are substrates of uptake in rat lungs. After loading of isolated perfused lungs with H-noradrenaline (MAO and catechol-O-methyltransferase (COMT) inhibited), the efflux of H-noradrenaline was measured for 30 min. When 1 μmol/l amezinium or 15 μmol/l debrisoquine was added for the last 15 min of efflux, there was a rapid and marked increase in the fractional rate of loss of H-noradrenaline, which was reduced by about 70% when 1 μmol/l desipramine was present throughout the efflux period. These results showed that both drugs were substrates for uptake in rat lungs. In lungs perfused with 1 nmol/l H-noradrenaline (COMT inhibited), 10, 30 and 300nmol/1 amezinium caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively. When MAOB was also inhibited, 10 nmol/l amezinium caused 84% inhibition of the deamination of noradrenaline by MAO-A in the lungs. In contrast, in hearts perfused with 10 nmol/l H-noradrenaline under conditions where the amine was accumulated by uptake (COMT, uptake and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline. The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake. Amezinium is much less potent as a MAO inhibitor in cells with the uptake transporter, such as the myocardial cells of the heart. The results also confirmed previous reports that amezinium is highly selective for MAO-A